ANI Pharma (ANIP) Tops Q2 EPS by 18c ; Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $2.21, $0.18 better than the analyst estimate of $2.03. Revenue for the quarter came in at $266 million versus the consensus estimate of $262.14 million.

FY 2026 Outlook:-

Revenue between $1.08 billion to $1.14 billion vs consensus $1.12 billion.
EPS between $9.19 to $9.69 vs consensus $9.42.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Nomad Foods Limited (NOMD) Tops Q2 EPS by 6c; offers guidance
• Tapestry (TPR) Tops Q4 EPS by 7c; offers guidance
• Pluralsight (PS) Reports Q2 EPS of $0.14